Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 11/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3083545 | 0.87 | CSF1R (0.47) | CSF1RRECQLACMSDPTGS2 | |
| Trifluoroacetic Acid SCHEMBL3082964 | 0.82 | PTGS2 (0.46) | CSF1RHDAC3HDAC1HDAC2ACMSD | |
| SCHEMBL3083546 | 0.81 | CSF1R (0.60) | CSF1R | |
| Trifluoroacetic Acid SCHEMBL4344859 | 0.79 | CSF1R (0.61) | CSF1RHDAC3HDAC1HDAC2 | |
| SCHEMBL4187145 | 0.76 | CSF1R (0.52) | CSF1RHDAC3HDAC1HDAC2PTGS2 | |
| SCHEMBL4189492 | 0.76 | CSF1R (0.52) | CSF1RHDAC3HDAC1HDAC2PTGS2 | |
| SCHEMBL3078707 | 0.76 | CSF1R (0.42) | CSF1RHDAC3HDAC1HDAC2PTGS2 | |
| SCHEMBL4179494 | 0.75 | CSF1R (0.52) | CSF1RHDAC3HDAC1HDAC2ACMSD | |
| SCHEMBL3082188 | 0.74 | CSF1R (0.45) | CSF1RHDAC3HDAC1HDAC2PSMB5 | |
| Trifluoroacetic Acid SCHEMBL2907602 | 0.72 | CSF1R (0.59) | CSF1RHDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | claimed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | claimed |
| US-7790724-B2 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-07 | — | — | US | disclosed |
| EP-2016057-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007123516-A1 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20060258666-A1 | c-fms kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258666-A1 | c-fms kinase inhibitors | FLT3, FES, FER | CSF1R 111/4885RECQL 1915/4885HDAC3 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.